ArticleClinical cancer research : an official journal of the American Association for Cancer Research2026
Integrated Multiomic Profiling Enhances Risk Stratification and Prognostication in Canine Osteosarcoma.
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
purposeOsteosarcoma is a heterogeneous and aggressive primary bone malignancy that affects both canines and humans. Standardized treatment regimens prescribed to both species do not address the complexity of the disease and thus have resulted in stagnant patient outcomes for more than 30 years. EXPERIMENTAL
designIn this study, we present the first multiomic dataset created from a large outcome-linked biobank of canine osteosarcoma treatment-naïve primary tumors, utilizing a computational framework designed to interrogate each dataset individually and to compare and integrate findings.
resultsThis exploratory work suggests that the presence of MYC amplification is a poor prognostic indicator in canines and highlights alterations in DNA damage repair, metabolism, and cell-cycle genes that are shared with humans. Furthermore, we show relationships between the local tumor immune microenvironment, TP53 mutations, MYC and PTEN status, and global gene methylation patterns.
conclusionsThis work highlights the complexity of the disease and provides new insight into the utility of prognostic biomarkers and potential druggable targets for future study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.